Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
HOWerewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc. (HOWL)

NASDAQ Global Select · Currency in USD
$0.98 ▼ -0.03 (-2.96%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.99 ▲ +0.01 (+0.51%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.01
Open
$1.01
Day's Range
$0.98 – $1.03
52 Week Range
$0.27 – $1.83
Volume
209,986
Avg. Volume
5,071,144
Market Cap
$47.63M
Beta (5Y Monthly)
0.29
PE Ratio (TTM)
--
EPS (TTM)
-$0.71
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.50

Profile: Werewolf Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
39
CEO
Daniel J. Hicklin

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate -$0.22 · Revenue est. $18.31M
DateEst.Actual
Jul 31, 2026-$0.28$0.08Beat
May 7, 2026-$0.32-$0.28Beat
Mar 27, 2026-$0.34-$0.20Beat
Nov 4, 2025-$0.39-$0.36Beat
Aug 14, 2025-$0.50-$0.40Beat
May 8, 2025-$0.44-$0.40Beat

Analyst view

Consensus price target
$6.50 ▲ +563.2%
Range $1.00 – $12.00
Rating: Buy
Buy 89% · Hold 11% · Sell 0%

Get free alerts on HOWL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.